2026

Ungewöhnliche Präsentation eines bullösen, multilokulären Erysipels am Rumpf – ein Fallbericht
Blomen C, Abeck F, Petersen F, Christolouka M, Booken N, Schneider S
DERMATOLOGIE. 2026 [Epub ahead of print].

2025

Identifying Cellular Immunodeficiency Through a Persistent Herpetic Whitlow
Blomen C, Abeck F, Booken N, Siemann‐Harms U, Schneider S
JEADV CLIN PRACT. 2025;4(4):848-850.

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg
Zimmermann N, Kött J, Zell T, Abedini A, Blomen C, Belz S, Deitert B, Heidrich I, Geidel G, Rünger A, Smit D, Weichenthal M, Ugurel S, Leiter U, Berking C, Gutzmer R, Schadendorf D, von Wasielewski I, Mohr P, Meier F, Herbst R, Utikal J, Terheyden P, Haferkamp S, Pföhler C, Kaatz M, Ziller F, Ulrich J, Meiss F, Bauer A, Schneider S, Gebhardt C
EUR J CANCER. 2025 [Epub ahead of print];234:116195.

2024

Irritant (Toxic) Contact Dermatitis Following Topical Use of Dimethylsulfoxide
Blomen C, Hildebrandt L, Schneider S
DTSCH ARZTEBL INT. 2024;121(21):714.

Posttransplantation course after allogeneic stem cell transplantation in a patient with advanced mycosis fungoides—Balancing relapse and rejection
Hansen-Abeck I, Blomen C, Abeck F, Torster L, Schneider S, Booken N
JEADV CLIN PRACT. 2024;3(5):1660-1664.

2021

Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?
Blomen C, Kött J, Hartung T, Torster L, Gebhardt C
CANCERS. 2021;13(24):.

Communication processes about predictive genetic testing within high-risk breast cancer families: a two-phase study design
Blomen C, Pott A, Volk A, Budäus L, Witzel I
SCI REP-UK. 2021;11(1):20178.

Letzte Aktualisierung aus dem FIS: 23.01.2026 - 05:08 Uhr